![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 38, 26878-26884, September 17, 1999
§,
,
From the
Molecular Genetics Group, John Curtin School
of Medical Research, Australian National University, G. P. O. Box 334, Canberra, Australian Capital Territory 2601, Australia and
¶ Centre for Medical Genetics, Department of Cytogenetics and
Molecular Genetics, Women's and Children's Hospital, North Adelaide,
South Australia 5006, Australia
| |
ABSTRACT |
|---|
|
|
|---|
Conjugation to the small eukaryotic protein
ubiquitin can functionally modify or target proteins for degradation by
the proteasome. Removal of the ubiquitin modification, or
deubiquitination, is performed by ubiquitin-specific proteases and is
an important mechanism regulating this pathway. Here we describe a
novel human ubiquitin-specific protease, USP3, initially identified as
a partial cDNA clone similar to one of two highly conserved
sequence regions common to all ubiquitin-specific proteases. We have
isolated a complete USP3 cDNA clone containing both of
these conserved sequence regions. The USP3 gene appears to
be single copy and maps to human chromosome 15q22.3. A USP3
probe detects two mRNA transcripts, one of which corresponds in
length to the cDNA. Both are expressed at low levels in all tissues
examined, with highest expression in pancreas. The USP3 protein is a
functional ubiquitin-specific protease in vitro, and is
able to inhibit ubiquitin-dependent degradation of both an
N-end Rule substrate and abnormal endogenous proteins in yeast. USP3 is
also only the second known ubiquitin-specific protease capable of
efficiently cleaving a ubiquitin-proline bond.
Ubiquitin conjugation to proteins is a highly regulated process,
controlled partly through the cascade of enzymes involved. These
enzymes, which include ubiquitin-activating enzymes,
ubiquitin-conjugating enzymes, and ubiquitin protein ligases, are
complemented by the deubiquitinating activity of enzymes termed
ubiquitin-specific proteases
(Ubps),1 deubiquitinating
enzymes or ubiquitin C-terminal hydrolases (reviewed in Refs. 1-3).
The Ubps can cleave either peptide bonds linking ubiquitin as part of a
precursor fusion protein, releasing free ubiquitin moieties, or cleave
bonds conjugating ubiquitin (post-translationally) to proteins. Based
on sequence similarity to conserved amino acid regions observed in the
first Ubps studied, numerous Ubps have been, and continue to be,
identified in many species, with 16 known to exist in yeast. Because
studies have shown that the presence of these motifs strongly
correlates with Ubp activity, not all these Ubps have actually been
functionally characterized as deubiquitinating enzymes. In humans, the
ability to cleave ubiquitin bonds has been illustrated for only four of
seven published Ubps; Unph, Tre-2, Hausp, and isopeptidase T (4-13).
Of the four characterized Ubps, each has its own characteristic
substrate specificity and role in ubiquitin-dependent
proteolysis, and it follows that novel deubiquitinating enzymes may
also play a distinct role in regulating the ubiquitin proteolytic pathway.
Fundamental to their regulatory role in ubiquitin-dependent
proteolysis is the ubiquitin cleavage activity exhibited by the Ubps.
Moreover, the cleavage specificity of individual Ubps dictates at which
point(s) they contribute to this regulation of
ubiquitin-dependent proteolysis. This is reflected by the
detrimental effects caused by overexpression of, or mutations to, the
Ubps, which have been best studied in yeast. Triple null mutants of the
yeast Ubp1p, Ubp2p, and Ubp3p are extremely sensitive to stress
conditions, presumably because of a reduction in the rate of
ubiquitin-dependent proteolysis (14). The yeast Doa4p
(Ubp4p) cleaves peptide or isopeptide bonds linking multi-ubiquitin
chains to peptide remnants following proteasomal degradation of the
ubiquitin-targeted protein (9). The doa4 null mutant causes
general inhibition of ubiquitin proteolysis and phenotype defects
ranging from slow growth to defects in DNA repair. Overexpression of
Doa4p increases the degradation rate of several substrates, indicating
that Doa4p is one rate-limiting factor in their degradation by the
ubiquitin-dependent proteolysis. When yeast Ubp14p (which
disassembles unanchored polyubiquitin chains) is deleted,
ubiquitin-dependent proteolysis is generally inhibited
because of the accumulated free chains inhibiting the proteasome (15).
However, overexpression of Ubp14p can inhibit the degradation of some
proteins although not affecting others, possibly because of its effects
on preassembled ubiquitin chains being attached to some substrates
(15). Thus, the characteristic substrate specificity of a Ubp greatly
influences its role in ubiquitin-dependent proteolysis.
In this study, we present the isolation and characterization of a novel
human ubiquitin-specific protease. We have adopted the nomenclature
suggested by the Human Genome Project nomenclature committee and have
termed this enzyme USP3. It is demonstrated that USP3 is a functional
Ubp, capable of cleaving the artificial ubiquitin-glutathione
S-transferase (GST) fusion protein in vitro. We have localized the USP3 gene to chromosome 15q22.3,
distinct from any known human Ubp. USP3 expression in yeast has a
general inhibitory effect on ubiquitin-dependent
proteolysis, as assayed with the degradation of L- Isolation of the Full-length USP3--
The cDNA clone
Hsaaadqei (EBI accession number Z21167) was obtained from the UK-Human
Genome Mapping Project as a Southern and Northern Hybridization Analyses--
The probe used
for Southern hybridization was a 760-bp
ScaI-EcoRI fragment from the 3' end of the
cDNA, whereas the probe for Northern hybridization was a 488-bp
BspHI-XbaI fragment, extending from bp 605 to bp
1093 of the USP3 sequence. Probes were radioactively labeled
with [ Chromosomal Localization--
Radiation hybrid mapping data was
searched at the National Center for Biotechnology Information. The
probe used for localization of the USP3 gene by fluorescence
in situ hybridization was the IMAGE cDNA clone 45276 obtained from Genome Systems (accession number H08387) in the vector
Lafmid BA. The probe was nick-translated with biotin-14-dATP and
hybridized in situ at a final concentration of 5 ng/µl to
metaphases from two normal males. The fluorescence in situ
hybridization method was modified from that previously described (21).
Chromosomes were stained before analysis with both propidium iodide (as
counterstain) and 4,6-diamidino-2-phenylindole for chromosome
identification). Images of metaphase preparations were captured by a
cooled CCD camera using the CytoVision Ultra image collection and
enhancement system (Applied Imaging Int Ltd.).
Expression of USP3--
Saccharomyces cerevisiae
BWG1-7A and BBY45 strains were cultured and transformed as described
elsewhere (22). To construct a GST-USP3 fusion expression plasmid, the
complete USP3 open reading frame was cloned as a
BamHI/HindIII fragment into the yeast
pRS316-based (16), single copy shuttle vector pRD56 (gift of Dr. Danesh
Moazed) to form pKT7. pKT7 expresses GST-USP3 from the GAL10
promoter. A second plasmid for the expression of GST-USP3 in yeast,
pKT8, was constructed by transferring the pGAL10/GST-USP3
insert from pKT7 into the high copy vector YEplac195 (23). The pRD56
plasmid, which expresses GST alone, was used as a negative control.
In Vitro Ubiquitin Cleavage Assay--
Preparation of the
[35S]-labeled Ub-GST fusion substrate required for
in vitro ubiquitin cleavage assays has been described previously (24). An extract from S. cerevisiae BWG1-7A
cells expressing either GST-USP3 (pKT8) or GST alone was prepared using a large scale version of an established method (17), except cell lysis
was achieved using a RF-I RIBI Cell Fractionator (Sorvall). A portion
of crude extract was retained as a positive control. The remaining
extract was incubated with goat anti-GST antibody (Amersham Pharmacia
Biotech) for 2 h at 4 °C, then 20 µl of 50% slurry of
protein G-Sepharose (Amersham Pharmacia Biotech) added and incubated
for a further 30 min. Following extensive washing of the pellet with TN
buffer (50 mM Tris, 150 mM NaCl, pH 7.4), 15 µl of TN buffer was added to the Sepharose beads, to which the
GST-USP3 protein was still attached. This Sepharose/protein slurry and
the crude extract as the positive control, were both used for in
vitro ubiquitin cleavage assays. This involved adding 5 µl of
[35S]-labeled Ub-GST fusion substrate, incubation at
37 °C for 1 h, electrophoresis on denaturing 12%
SDS-polyacrylamide gel (25), and fluorography as described elsewhere
(26).
In Vivo Ubiquitin Cleavage and Proteolysis Assays--
Plasmids
pUb23-P and pUb23-L, which express Ub-P- Canavanine Sensitivity Assay--
BBY45 yeast cultures
transformed with the plasmids expressing GST or GST-USP3 (see above)
were grown for 48 h in galactosidase + Gro-medium at 30 °C as
described previously (30), subcultured into SD-Ura/Gal, and grown
overnight at 30 °C until they reached A600 = 0.5-1.0. The yeast cultures were serially diluted and plated in
triplicate on selective media (SD-uracil, -arginine; Ref. 17) containing 0, 0.5, 1, or 1.5 µg/ml canavanine. Sensitivity to canavanine was determined by expressing the number of colonies present
at each concentration of canavanine as a percentage of those present at
0 µg/ml canavanine (control).
Completion of the Hsaaadqei/USP3 cDNA Clone Sequence--
We
identified an EST cDNA clone arising from the UK Human Genome
Mapping Project (accession number Z21167, clone name Hsaaadqei) by
similarity to the conserved Ubp Cys-box originally identified in the
yeast Ubp1p, Ubp2p, and Ubp3p enzymes (14). Sequencing of the Hsaaadqei
cDNA clone, followed by sequence comparison to computer data bases
revealed that this clone was a fusion of two clones, a partial Ubp-like
clone containing the conserved Cys-box, and a second cDNA clone
derived from the human thyroid receptor-interacting protein gene Trip1
(HUMTRIP1). These were joined together by their 5' ends, producing the
~1.7-kb Hsaaadqei cDNA clone presumably as an artifact of
cDNA library construction. Using the partial Ubp-like portion
(~770-bp, renamed USP3) as a probe for screening a human
testis library, several positive clones, including C2 and C3 (clone 2 and clone 3) were obtained. The products of EcoRI digests of
these clones were sequenced. Clone C2 produced two EcoRI
fragments, C2.1 and C2.2 (Fig.
1A). Clone C3 produced three EcoRI fragments, C3.1, C3.2, and C3.3 (Fig. 1A).
The sequence of the C2.1 and C3.2 fragments confirmed the 770-bp
USP3 sequence, including a 64-bp extension 5' to the
SacI site used to obtain the partial 770-bp
SacI/EcoRI USP3 cDNA clone from
Hsaaadqei. The sequences from C2.2 and C3.1 were not similar to
USP3 as they presumably represented adjoining
EcoRI fragments. The necessary overlaps were found through
subsequent detection of the EST clone H08387 by data base searches with
the 770-bp USP3 sequence. The known sequence of the
USP3 cDNA was thus extended to 2.32-kb, containing both
the Cys- and the His-conserved sequence boxes common to all Ubps, an
open reading frame (ORF) extending from a start codon at base pair 100 to a stop codon at bp 1,666, and a polyadenylation signal and poly(A)
tail downstream of this ORF (Fig. 1B). The 3' end of the
sequence contains a well defined mammalian polyadenylation signal
AATAAA (bp 2,263-2,268), followed by a diffuse GU-rich (GT-rich in
cDNA) sequence spanning approximately 28 bp until the actual site
of polyadenylation (bp 2,297) (31-33). At the 5' end of the sequence,
located 5' to the start codon, is a GC-rich region, consistent with a
5'-untranslated region. The flanking nucleotide sequence around this
initiation codon, containing a G at Alternative Splicing in USP3--
One EST identified through data
base searches with the USP3 sequence contained an additional
insert of 138 bp. This clone, GenBankTM accession number
H93896, deviates from the USP3 sequence at bp 383, for 138 bp, then matches USP3 sequence identically from bp 384 (Fig.
1A). This raises the possibility that alternative splicing
of the USP3 gene occurs. The only other EST clone that spans
this region of USP3 (accession number AI525838) does not
contain this additional sequence, and the 138-bp sequence was not found
to be similar to any other EST clone apart from itself. As this extra
sequence introduces stop codons in all three frames, it is most likely
a splicing error rather than a normally alternatively spliced exon, as
it would produce a severely truncated protein.
Sequence comparisons between the amino acid sequence deduced from the
ORF of the complete USP3 cDNA clone and other known Ubps
did not identify any strong sequence identities or similarities aside
from a number of conserved regions, which include the Cys-, His-, Asp-
and KRF-boxes (Figs. 1A and 2). Among the 16 yeast Ubps,
USP3 is most similar to Ubp8p (27% identity/40% similarity over the
whole 471 residues of the latter; Fig.
2). The function of Ubp8p is not known
(2).
Southern and Northern Hybridization Analysis--
Southern blot
analysis using a fragment spanning bp 1564 to 2324 of the
USP3 cDNA and restriction-enzyme-digested human genomic DNA produced one or at most two hybridizing bands with each enzyme, consistent with a single copy gene (Fig.
3; see also Fig. 1). The presence of two
bands in the EcoRI digest is presumably due to at least one
intron occurring within the region covered by the probe. If any closely
related gene to USP3 was present, it must have an identical
restriction map, at least with the enzymes used here.
Northern hybridization analysis of total RNA did not detect specific
bands (data not shown). Hybridization of a multiple human tissue
poly(A)+ RNA Northern blot (CLONTECH)
with a USP3 probe produced a band representing a 2.45-kb
transcript and a more weakly hybridizing band of 5.8 kb (Fig.
4A). The 5.8-kb transcript,
and a third very weakly hybridizing 4.0-kb transcript, were more
evident on longer exposures (not shown). The 2.45-kb mRNA
corresponds to the 2.3-kb cDNA sequence, the difference accounted
for by additional poly(A) tail and possibly additional 5'-untranslated
region not present in the cDNA. The functional significance of the
two major transcripts is not known, but the 5.8-kb transcript may be
because of either the presence of a gene highly homologous to
USP3, or an alternatively polyadenylated/spliced transcript
of USP3 (see "Discussion").
Both the 2.45- and 5.8-kb USP3 transcripts were expressed in
all the human tissues examined in approximately the same proportion to
each other, including the heart, brain, placenta, lung, liver, skeletal
muscle, kidney, and pancreas tissues. Abundance of both transcripts was
reduced in brain tissue (relative to the Chromosomal Localization of USP3--
An USP3 EST
(GenBankTM accession number H08388) had been mapped by
radiation hybrid panel analysis to the chromosomal region 15q22-15q22.3, marker interval D15S159-D15S125, 58.8-63.8cM. To confirm this assignment, we obtained the same clone from Genome Systems
(IMAGE cDNA clone 45276), which spans bp 600-2,324 of the
USP3 cDNA (Fig. 1A), and used it as probe for
fluorescence in situ hybridization. Twenty metaphases from a
normal male were examined for fluorescent signal. All of these
metaphases showed signal on one or both chromatids of chromosome 15 in
the region 15q22-15q22.3; 70% of this signal was at 15q22.3 (data not
shown), confirming the RH mapping result, and indicating that no
closely related sequences were present elsewhere in the genome. There was a total of 12 nonspecific background dots observed in these 20 metaphases. A similar result was obtained from hybridization of the
probe to 15 metaphases from a second normal male (data not shown).
USP3 Exhibits Ubiquitin Cleavage in Vitro--
The USP3 protein
contains conserved sequence motifs found in all active Ubps (Fig. 2).
These motifs contain a conserved cysteine residue and two histidine
residues, respectively, that are thought to form part of the active
site of these thiol proteases (14). To confirm that the presence of
these conserved regions in USP3 correlates with Ubp activity, we
initially attempted to express the USP3 protein in Escherichia
coli. Unlike all previous Ubps expressed in E. coli,
plasmids expressing USP3 could not be maintained in this bacteria,
presumably because of toxicity (data not shown). USP3 was therefore
expressed in Saccharomyces cerevisiae. Because S. cerevisiae has 16 Ubps, it was necessary to isolate the USP3 protein to assay its ubiquitin cleavage ability. USP3 was, therefore, expressed as a GST-USP3 fusion and isolated by immunoprecipitation using anti-GST antibody. (Attempts to purify GST-USP3 by glutathione affinity chromatography were unsuccessful (data not shown).) It should
be noted that GST-USP3 was expressed in yeast at very low levels,
barely detectable by Western immunoblot analysis with an anti-GST
antibody (data not shown). The assay was conducted using the
GST-USP3·antibody·protein G-Sepharose complex. The USP3 ubiquitin
cleavage activity was assayed against an artificial linear
35S-labeled ubiquitin GST-fusion protein (Fig.
5) (5, 35). Whereas the isolated GST
protein alone (control) exhibited no cleavage of the Ub-GST fusion
protein, an increase in cleavage of this fusion by the GST-USP3 protein
was apparent, although at a very low level. This result is reinforced
by evidence for USP3 cleavage of ubiquitin- USP3 Inhibits Degradation of L-
Co-expression of GST-USP3 with Ub-P- USP3 Disrupts Ubiquitin-dependent Proteolysis--
One
role of ubiquitin-dependent proteolysis is to selectively
eliminate abnormal proteins, protecting against their toxic effects
(28, 29, 40). To evaluate the involvement of USP3 in
ubiquitin-dependent proteolysis, we examined the effect of GST-USP3 expression in cells grown on canavanine, an analogue of
arginine. When incorporated into proteins, canavanine results in
abnormal proteins that are degraded by the ubiquitin pathway. Disruption of this process renders cells more susceptible to the toxic
effects of misfolded proteins. Expression of GST-USP3 from the low copy
number plasmid pKT7 produced a negative (but not statistically
significant) trend in viability with increasing canavanine
concentration, indicating that USP3 was interfering with this process
(Fig. 7). When GST-USP3 was expressed from the high copy plasmid pKT8,
it caused a significant decrease in the number of viable cells at high
concentrations of canavanine (1-1.5 µg/ml), confirming this trend
and consistent with USP3 causing an inhibition of general
ubiquitin-dependent proteolysis. The more trivial
explanation, that the USP3 protein is toxic in its own right, does not
apply, because there was no effect of GST-USP3 expression on cell
viability in the absence of canavanine (raw viable cell data from 0 µg/ml canavanine lanes, Fig. 7; data not shown).
Through this study the complete cDNA of a new and previously
uncharacterized human Ubp has been isolated. According to a systematic nomenclature proposal for human Ubps (41), we have named this enzyme
USP3, and the new names for other human Ubps are presented parenthetically in the following discussion. The USP3 amino acid sequence contains two highly conserved sequence regions, the Cys- and
His-boxes, containing a conserved cysteine residue and two conserved
histidine residues, respectively. These regions were originally
proposed to contain the active site Cys and His residues of these thiol
proteases (14), and mutagenesis studies have confirmed this in several
Ubps (e.g. Refs. 5, 9, 15, and 42-44). USP3 also contains
two other conserved Ubp regions, the Asp-, or Gln-box, and the KRF-box,
both of presently unknown function (3, 8, 10). Unlike all Ubps studied
to date, which have been successfully expressed in E. coli
(48), expression of the USP3 protein in E. coli was
unsuccessful, presumably because of toxicity, and thus an alternative
expression system was required. Expression of USP3 in yeast as a GST
fusion was successful, albeit at very low levels. The ubiquitin
cleavage activity exhibited by USP3 is consistent with the presence of
the Cys- and His-boxes, containing conserved residues that in other
Ubps have been found to be functionally important (5, 9, 15,
42-44).
Southern hybridization analysis of the USP3 gene suggests
that it is a single copy gene. The USP3 gene mapped uniquely
to human chromosome 15q22.3 by both radiation hybrid and fluorescence in situ hybridization mapping, with no secondary
hybridization signal detected, and it can be inferred that no closely
related sequences exist elsewhere in the genome. Most Ubp genes have
been mapped, and in humans these include DFFRX(USP9X) and
DFFRY(USP9Y), which localize to the X and
Y chromosomes, respectively (11, 12); UNP(USP4),
which localizes to 3p21.3 (4); ISOT-1/2(USP5) to 12p13 (45);
and ISOT-3(USP13) to 3q26.2 (46). At present, only the mouse
DUB family of Ubps forms a cluster of at least 4 genes on chromosome 7 (43, 44). While this manuscript was in preparation, Fujiwara et
al. (52) reported the identification and chromosomal localization
of USP1, a novel human USP of 785 amino acids/88 kDa, that localizes to
chromosome 1p31.3-p32.1. USP1 is clearly distinct to USP3 in size,
sequence, and chromosomal location, and notably was also identified by
a random cDNA sequencing program.
A USP3 probe hybridizes to a transcript of 5.8 kb in
addition to the expected 2.45-kb mRNA in all tissues examined.
Similar large variation in transcript sizes have been observed in some other Ubps. Most nonyeast Ubps, including Unp, Unph, Hausp,
fam, and faf, also have two RNA transcripts (4,
6, 47-50). The two Unp transcripts (3.5 and 3.7 kb) result from
alternate polyadenylation sites at the 3' end of the sequence (4),
whereas the mouse fam (11.5, 10, and 8.5 kb) and
faf (8.1 and 8.2 kb) mRNAs also vary only in their
3'-untranslated regions. In addition, both Unph and ISOT-1/2
give rise to two transcripts because of alternate splicing of small
coding region exons 8, 10, 48). We did identify one EST clone that
included an extra 138 bp within the USP3 coding region, but this
presumably represents a splicing error, because it would disrupt the
reading frame. ISOT-3 gives rise to three transcripts of 3.5 kb (the expected size from the cDNA), 5.5 and 8.5 kb, presumably
due to alternate polyadenylation sites (46). The USP3 5.8-kb
transcript may thus also be due to different lengths of the
3'-untranslated region. Further analysis of this 5.8-kb transcript,
together with sequencing of the USP3 gene, should determine
the reason for this large variation in transcript size, and provide a
better understanding of its functional significance.
The low level of USP3 expression, emphasized by an inability
to detect USP3 transcripts on Northern blots of total RNA,
reflects the situation of another human Ubp, Hausp(USP7): transcripts
of Hausp, like USP3, were also detected only on blots of
poly(A)+ RNA (6). USP3 is expressed at
approximately equal levels in heart, placenta, lung, liver, kidney, and
skeletal muscle, at relatively high levels in the pancreas, and at much
lower levels in brain. Mouse Unp, and human Unph, DFFRX, DFFRY, are
expressed in all tissues studied (4, 11, 12, 48-50). In contrast, ISOT-1/2 and ISOT-3 show marked tissue-specific
expression; the former strong in brain, and the latter strong in testes
and ovary (45, 46). Different expression levels in different tissues may reflect different abundance of the substrate(s) whose
ubiquitination state is regulated by these Ubps.
An unusual activity exhibited by USP3 is the ability to cleave the
ubiquitin-proline bond. USP3 is only the second characterized Ubp able
to cleave the glycine76-proline in the Ub-P- The ability of USP3 to cleave linear ubiquitin fusion proteins suggests
that USP3 could participate in the generation of free ubiquitin
molecules from ubiquitin precursor fusions. This may not, however, be
its primary function, because the pulse-chase analysis of L- It is difficult to suggest what the specific deubiquitinating function
of USP3 may be at present. Our observed minor disruption to general
ubiquitin-dependent proteolysis suggests that USP3 may
participate in regulation of ubiquitin-dependent
proteolysis of key substrate(s) of the ubiquitin pathway, rather than
in a general regulatory role. The orthologue of the key substrate(s) whose ubiquitin-dependent degradation USP3 may help
regulate in human cells may actually be absent from yeast. Complete
analysis of the USP3 protein in the future will require study of USP3
in human tissue and cell lines, because only in its natural
physiological environment will the impact of USP3 on
ubiquitin-dependent pathways be accurately assessed.
Nevertheless, this initial characterization of USP3 has provided an
insight into its role and significance as a potential regulatory
component of the ubiquitin-dependent proteolytic pathway.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-gal, a specific
introduced N-end rule substrate of the ubiquitin-dependent
proteolytic pathway, and on the degradation of abnormal endogenous
proteins. In addition, USP3 is able to efficiently cleave the
ubiquitin-proline bond. To date this cleavage activity has only been
attributed to the mouse Ubp, Unp, and its human homolog, Unph (5).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
NM1149 phage clone. The ~1.7-kb
EcoRI insert was subcloned into the vector pRS316 (16) and,
following restriction endonuclease mapping, completely sequenced
(Sequenase version 2.0, U. S. Biochemical Corp.) to reveal an artifact
of two fused cDNA clones (see "Results"). The Ubp-like portion
was isolated as a SacI/EcoRI fragment, termed USP3, and used for subsequent experiments. The partial
cDNA clone was used as a random primed probe (Megaprime; Amersham
Pharmacia Biotech) for screening a
gt11 phage human testis tissue
cDNA library (CLONTECH) (17). After selecting
positive clones derived from tertiary screening, phage DNA was isolated
(Promega Wizard
Preps purification system) and the inserts
amplified using
-specific primers (New England Biolabs, catalogue
numbers 1218F and 1222R). The polymerase chain reaction products were
digested with EcoRI and ligated into pBluescript and
sequenced. Computer sequence data bases were searched using the BLAST
algorithm (18); this identified two expressed sequence tag (EST)
cDNAs, which confirmed the fragment order and sequence of the
majority of the 2,324-bp sequence. The open reading frame was amplified
by the polymerase chain reaction using specific oligonucleotide primers
(USP3BamHI, 5'-d(TCGGATCCATGGAGTGTCCACACCTGAG);
USP3HindIII, 5'-d(ATAAAGCTTGCAGCCTTGAGAGACAAGC)) and a proofreading DNA polymerase to reduce errors
(Pfu-Turbo, Stratagene). The product was digested with
BamHI/HindIII and ligated into protein expression
vectors as required (see below).
-32P]dATP using random priming (Megaprime;
Amersham Pharmacia Biotech). Genomic DNA was isolated from human blood
samples (19) and 10 µg digested overnight at 37 °C with
BamHI, EcoRI, PstI, or
XbaI. The digests were electrophoresed on 1× TAE, 1%
agarose gel, and capillary blotted (20) onto Hybond N+
(Amersham Pharmacia Biotech), with hybridization carried out as
specified by the membrane manufacturer. Northern hybridization used a
CLONTECH Premade Multiple Human Tissue Northern
blot (catalog no. 7760), containing ~2 µg of mRNA per lane,
according to the manufacturer's instructions.
-gal and Ub-L-
-gal fusion
proteins, respectively, from a hybrid CYC-GAL10 promoter on
a yeast high copy plasmid (27) were used to express
-gal reporter
proteins. Steady state
-gal activity was determined using
o-nitrophenyl-
-D-galactoside as a substrate
as described elsewhere (17). Degradation of Ub-P-
-gal and
L-
-gal proteins in yeast was assayed by pulse-chase
labeling with [35S]methionine, extraction,
immunoprecipitation with a monoclonal antibody to
-gal (Promega),
electrophoresis in a 6% SDS-polyacrylamide gel (25), and fluorography
(26).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3 and +4 (Kozak consensus
sequence; Ref. 34) is consistent with the ATG at bp 100 being the
actual initiation codon. However, as there are no in-frame stop codons
upstream of the start codon at bp 100, we cannot rule out a further
upstream initiation codon. The present ORF would produce a protein of
approximately 59 kDa, and the cDNA is consistent in length with
subsequent Northern blot hybridization analysis (see below). Alignment
of multiple USP3 ESTs detected through data base searches
with the USP3 sequence in Fig. 1 confirmed the latter was
the consensus. While this manuscript was under review, several EST
clones appeared in the data base that confirm the 5' end of the
cDNA, and two ESTs suggest that the sequence in Fig. 1B
may be preceded by GGCCGAGCGC (accession numbers AI525838, AA371059,
AA356126, AA361954).

View larger version (72K):
[in a new window]
Fig. 1.
Full-length cDNA encoding
USP3. A, schematic representation of the complete
USP3 cDNA. The complete 2.3-kb USP3 cDNA
sequence, containing an open reading frame, was derived from three
clones, C2.1, C2.2, and C3.1, obtained through library screening. The
complete USP3 cDNA fragment was assembled from C2.1 and
an EST clone, accession number H08387/8, identified through data base
searches for similarity to USP3. Another USP3 EST
clone, H93896, is also shown. H93896 contains an additional 138-bp
sequence insert (represented by the triangle) at bp 383 in
the USP3 sequence. Also shown are the probes used for
Southern and Northern hybridization analyses. E,
EcoRI; B, BspHI; S,
ScaI; X, XbaI. B,
full-length cDNA encoding USP3 and deduced amino acid
sequence. The conserved cysteine- and histidine-containing regions
(Cys- and His-boxes, respectively) are underlined with double
lines, whereas the conserved Asp- and KRF-boxes are underlined by
single lines. The polyadenylation signal AATAAA at bp 2263 is also underlined.

View larger version (41K):
[in a new window]
Fig. 2.
Structure and conserved sequence regions of
USP3. A, Schematic structural representation of USP3, mouse Unp,
and Ubp8p, the yeast Ubp most similar to USP3. Positions of the
conserved sequence regions that contain a conserved Cys residue
(C) and two His residues (H), respectively, are
shown. Amino acid residues are numbered. B and
C, amino acid sequences of the conserved Cys- (B)
and His- (C) boxes are shown for USP3, mouse Unp, human
Tre-2, chicken Ubp41, and yeast Ubp8p, in the standard single letter
code.

View larger version (52K):
[in a new window]
Fig. 3.
Southern blot hybridization analysis of the
USP3 gene. DNA isolated from human leukocytes was
digested with the restriction endonucleases BamHI
(lane 2), EcoRI (lane 3),
PstI (lane 4), and XbaI (lane
5), electrophoresed on 1× TAE/ethidium bromide agarose gel
against end-labeled
HindIII DNA markers (lane
1). The resolved DNA was capillary blotted and probed with a
760-bp USP3 fragment (see Fig. 1). The hybridized membrane
was washed (15 min, 2× SSC, 0.1%SDS, 25 °C; 15 min, 1× SSC,
0.1%SDS, 25 °C; 15 min, 0.1× SSC, 0.1%SDS, 65 °C) and
autoradiographed 5 days.

View larger version (97K):
[in a new window]
Fig. 4.
Expression of USP3 in human
tissues. A, a Northern blot of multiple human tissue
poly(A)+ mRNA (CLONTECH) was probed
with a radioactively labeled USP3 fragment (Fig.
1A). Sizes of RNA markers are shown on the left
in kilobases, whereas tissues are listed above the lanes.
The sizes of the hybridizing fragments are indicated on the
right. B, hybridization with
-actin control,
used to normalize USP3 tissue expression. Two forms of
-actin are present in the heart and skeletal muscle.
-actin control), whereas in
both pancreas and, to a lesser extent, kidney tissue, increased
expression is apparent.
-galactosidase fusions
in vivo (see below).

View larger version (67K):
[in a new window]
Fig. 5.
In vitro cleavage of Ub-GST by USP3.
Recombinant GST and GST-USP3 proteins were isolated by
immunoprecipitation and assayed for in vitro cleavage of a
35S-labeled Ub-GST fusion substrate. A negative control
(phosphate-buffered saline) and a positive control (yeast cell extract
containing 16 endogenous Ubps) were also included in the assay, as
indicated above the lanes. The controls and the
immunoprecipitated proteins, still attached to the protein G-Sepharose,
were mixed with the 35S-labeled Ub-GST fusion substrate and
incubated at 37 °C for 1 h. Samples were resolved by
SDS-polyacrylamide gel electrophoresis in a 12% gel and fluorographed
(see "Experimental Procedures"). Bands containing Ub-GST, GST
alone, and Ub are indicated on the left.
-Gal and Cleaves the
Ubiquitin-Proline Bond in Vivo--
The
Ub-X-
-galactosidase (Ub-X-
-gal) fusion
proteins are commonly used as model substrates of
ubiquitin-dependent proteolysis in yeast (e.g.
see Refs. 26, 27, 36, 37). We investigated the effect of USP3
expression on ubiquitin-dependent degradation of L-
-gal,
an N-end rule substrate, and Ub-P-
-gal, a non-N-end rule substrate,
in yeast. Yeast Ubps efficiently cleave Ub-L-
-gal to L-
-gal, an
N-end rule substrate, whereas yeast Ubp activity against the
ubiquitin-proline bond of Ub-P-
-gal is 20-fold slower than for other
amino acids (27, 38, 39). At present, only the mouse Ubp, Unp, and its
human homolog Unph have been found to efficiently cleave the
ubiquitin-proline bond (5). In yeast, L-
-gal has a half-life of ~3
min, whereas the uncleaved Ub-P-
-gal is degraded with a half-life of
~7 min (27). Measurement of steady-state
-gal activity showed that
expression of GST-USP3 from the high copy plasmid (pKT8) increased the
activity of L-
-gal and Ub-P-
-gal 2-3-fold and 16-fold,
respectively (Fig. 6A). This suggested that USP3 might be inhibiting the
ubiquitin-dependent degradation of both these proteins
and/or, in the case of Ub-P-
-gal, cleaving the Ub-proline bond to
generate the stable P-
-gal protein. The inhibitory effect of USP3 on
the degradation of these proteins was examined further through
pulse-chase assays (Fig. 6B). In the presence of GST-USP3,
expressed from both low copy (data not shown) and high copy (Fig.
6B) plasmids, there was a clear increase in levels of
L-
-gal protein at later time points compared with the control.
Quantification of the half-life over the 0-10 min chase period
revealed that the half-life increased from ~3 min in the control, to
~6.5 min in the high copy GST-USP3 expressing cells. The simplest
explanation for this would be that USP3 possessed a "trimming"
isopeptidase activity, and was shortening the multi-ubiquitin chain on
L-
-gal, thus reducing its efficiency as a proteasome targeting
signal. Although no change is apparent from Fig.
7B, a small difference in high
molecular weight conjugates may account for the small change in
half-life observed.

View larger version (63K):
[in a new window]
Fig. 6.
Effect of USP3 expression on
ubiquitin-dependent proteolysis of
L-
-gal and
Ub-P-
-gal. A, yeast
co-expressing either GST alone (control), the GST-USP3
protein from a single copy plasmid (pKT7), or from a high
copy plasmid (pKT8) and either Ub-L-
-gal (left
panel) or Ub-P-
-gal (right panel)were assayed for
-gal activity against
o-nitrophenyl-
-D-galactoside. The values
shown are the means ± S.D. (error bars) of at least
three independent measurements. B, yeast expressing either
Ub-L-
-gal (lanes 1-6) or Ub-P-
-gal (lanes
7-12), and GST protein (lanes 1-3, 7-9),
or GST-USP3 from a high copy plasmid pKT8 (lanes 4-6,
10-12) were pulse-labeled with
[35S]methionine for 5 min, and chased in the presence of
unlabeled methionine and cycloheximide for either 0, 10, or 30 min, as
indicated below the lanes. Extracts were immunoprecipitated
with a monoclonal antibody to
-gal, resolved by SDS-polyacrylamide
gel electrophoresis, and fluorographed (see "Experimental
Procedures"). Bands representing cleaved X-
-gal,
uncleaved Ub-X-
-gal, and Ub-X-
-gal species
bearing a multi-ubiquitin chain (Ubn-X-
-gal)
are indicated on the left. An arrow indicates an
~90-kDa degradation product of
-gal (26).

View larger version (17K):
[in a new window]
Fig. 7.
Effects of USP3 expression on
ubiquitin-dependent proteolysis of abnormal proteins.
Yeast expressing the GST protein (control), the GST-USP3
protein from a low copy plasmid (pKT7), or the GST-USP3
protein from a high copy plasmid (pKT8), were grown on media
containing various concentrations of canavanine (x axis).
Cell viability was expressed as a percentage of the cells growing on no
canavanine (y axis). The means ± S.D. of viable cells
were calculated from triplicate platings.
-gal resulted in a substantial
increase in levels of a protein of the size of P-
-gal (Fig.
6B). Because P-
-gal is a stable protein in the yeast
N-end rule (38), this accounts for the substantially increased
steady-state
-gal levels observed (Fig. 6A). The
proportion of cleavage was higher when GST-USP3 was expressed from the
high copy plasmid than the low copy plasmid (data not shown),
consistent with a dose effect. It is hard to judge whether USP3 has an
isopeptidase activity against the multi-ubiquitin chain attached to
Ub-P-
-gal, as the amount of Ub-P-
-gal available for
multi-ubiquitination diminishes as more is cleaved to P-
-gal.
Because similar results were reported recently for the mouse Unp and
human Unph, together with a demonstration that this cleavage occurs
precisely at the ubiquitin-proline junction (5), it can be inferred
that USP3 is also cleaving this bond.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-gal fusion.
To date, only the mouse Unp and its human homolog, Unph, have
demonstrated this ability. The significance of this activity is not
known at present; however, a naturally occurring ubiquitin-like protein
with a C-terminal proline residue linking it to a 590-amino acid
protein (known together as An1p) has been identified in Xenopus
laevis (51). The ability of USP3 to cleave this protein is
currently being investigated.
-gal
degradation indicates that USP3 can inhibit ubiquitin-dependent proteolysis of this protein, the
simplest explanation being a trimming isopeptidase cleavage of
ubiquitin moieties from the multi-ubiquitin chain targeting it for
degradation. The ability of USP3 to inhibit
ubiquitin-dependent proteolysis in yeast is further
emphasized by its effect on the degradation of abnormal,
canavanine-containing proteins. An alternate explanation is that USP3
may have an isopeptidase-T/Ubp14p-like activity in cleaving unanchored
ubiquitin chains, because overexpression of Ubp14 in yeast has been
observed to also stabilize the N-end rule substrate L-
-gal (but not
other substrates; Ref 15). As also suggested for Ubp14p, USP3 may form
aberrant complexes with other components of the ubiquitin system
and cause a general impairment of function (15).
| |
FOOTNOTES |
|---|
* This work was supported by grants from the J. H. and J. D. Gunn Medical Research Foundation, the National Health and Medical Research Council of Australia (to H. J. E. and G. R. S.), and the Australian Research Council (to R. T. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession number AF073344.
§ Current address: Dept. of Biochemistry, Molecular Biology and Cell Biology, MLS 3165, 2225 N. Sheridan Rd., Northwestern University, Evanston, IL 60208.
To whom correspondence should be addressed. Tel.:
61-2-6249-3824; Fax: 61-2-6249-4712; E-mail:
Rohan.Baker@anu.edu.au.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
Ubp, ubiquitin-specific protease;
Ub, ubiquitin;
USP3, human
ubiquitin-specific protease 3 cDNA/gene;
USP3, human
ubiquitin-specific protease 3 protein;
bp, base pair(s);
kb, kilobase pair(s);
GST, glutathione S-transferase;
-gal,
-galactosidase;
Ub-X-
-gal, ubiquitin-X-
-gal fusion, where X is one of the
20 amino acids;
ORF, open reading frame;
EST, expressed sequence
tag.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Haas, A. L., and Siepmann, T. J. (1997) FASEB J. 11, 1257-1268[Abstract] |
| 2. | Hochstrasser, M. (1996) Annu. Rev. Genet. 30, 405-439[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Wilkinson, K. D. (1997) FASEB J. 11, 1245-1256[Abstract] |
| 4. | Gray, D. A., Inazawa, J., Gupta, K., Wong, A., Veda, R., and Takahashi, T. (1995) Oncogene 10, 2179-2183[Medline] [Order article via Infotrieve] |
| 5. |
Gilchrist, C. A.,
Gray, D. A.,
and Baker, R. T.
(1997)
J. Biol. Chem.
272,
32280-32285 |
| 6. | Everett, R. D., Meredith, M., Orr, A., Cross, A., Kathoria, M., and Parkinson, J. (1997) EMBO J. 16, 1519-1530[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Falquet, L., Paquet, N., Frutiger, S., Hughes, G. J., Hoang-Van, K., and Jaton, J.-C. (1995) FEBS Lett. 359, 73-77[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Falquet, L., Paquet, N., Frutiger, S., Huhes, G. J., Hoang-Van, K., and Jaton, J.-C. (1995) FEBS Lett. 376, 233-237[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Papa, F. R., and Hochstrasser, M. (1993) Nature 366, 313-319[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Wilkinson, K. D., Tashayev, V. L., O'Connor, L. B., Larsen, C. N., Kasperek, E., and Pickart, C. M. (1995) Biochemistry 34, 14535-14546[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Jones, M. H.,
Furlong, R. A.,
Burkin, H.,
Chalmers, J.,
Brown, G.,
Khwaja, O.,
and Affara, N. A.
(1996)
Hum. Mol. Genet.
5,
1695-1701 |
| 12. |
Brown, G. M.,
Furlong, R. A.,
Sargent, C. A.,
Erickson, R. P.,
Longepied, G.,
Mitchell, M.,
Jones, M. H.,
Hargreave, T. B.,
Cooke, H. J.,
and Affara, N. A.
(1998)
Hum. Mol. Genet.
7,
97-108 |
| 13. | Janssen, J. W. G., Schleithoff, L., Bartram, C. R., and Schulz, A. S. (1998) Oncogene 16, 1767-1772[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Baker, R. T.,
Tobias, J. W.,
and Varshavsky, A.
(1992)
J. Biol. Chem.
267,
23364-23375 |
| 15. | Amerik, A. Y., Swaminathan, S., Krantz, B. A., Wilkinson, K. D., and Hochstrasser, M. (1997) EMBO J. 16, 4826-4838[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Sikorski, R. S.,
and Hieter, P.
(1989)
Genetics
122,
19-27 |
| 17. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 18. | Altshul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Grünebaum, L., Caznave, J. P., Camerino, G., Kloepfer, C., Mandel, J. L., Tolstoshev, P., Jaye, M., De-la-Salle, H., and Lecocq, J. P. (1984) J. Clin. Invest. 73, 1491-1495 |
| 20. | Ausübel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., Struhl, K., Albright, L. M., Coen, D. M., and Varki, A. (1989) Current Protocols in Molecular Biology , John Wiley & Sons, Inc., and Greene Publishing Associates, New York |
| 21. | Callen, D. F., Baker, E., Eyre, H. J., Chernos, J. E., Bell, J. A., and Sutherland, G. R. (1990) Ann. Genet. 33, 219-221[Medline] [Order article via Infotrieve] |
| 22. |
Ito, H.,
Fukada, Y.,
Murata, K.,
and Kimura, A.
(1983)
J. Bacteriol.
153,
163-168 |
| 23. | Gietz, R. D., and Sugino, A. (1988) Gene 74, 527-534[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Tobias, J. W.,
and Varshavsky, A.
(1991)
J. Biol. Chem.
266,
12021-12028 |
| 25. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Baker, R. T.,
and Varshavsky, A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1090-1094 |
| 27. |
Bachmair, A.,
Finley, D.,
and Varshavsky, A.
(1986)
Science
234,
179-185 |
| 28. | Seufert, W., and Jentsch, S. (1990) EMBO J. 9, 543-550[Medline] [Order article via Infotrieve] |
| 29. | Seufert, W., McGrath, J. P., and Jentsch, S. (1990) EMBO J. 9, 4535-4541[Medline] [Order article via Infotrieve] |
| 30. | Bartel, B., Wunning, I., and Varshavsky, A. (1990) EMBO J. 9, 3179-3189[Medline] [Order article via Infotrieve] |
| 31. | Birnstiel, M. L., Busslinger, M., and Strub, K. (1985) Cell 41, 349-359[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Proudfoot, N. J., and Brownlee, G. G. (1976) Nature 263, 211-214[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Proudfoot, N. (1991) Cell 64, 671-674[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Kozak, M.
(1991)
J. Biol. Chem.
266,
19867-19870 |
| 35. |
Baker, R. T.,
Smith, S. A.,
Marano, R.,
McKee, J.,
and Board, P.
(1994)
J. Biol. Chem.
269,
25381-25386 |
| 36. | Johnson, E. S., Bartel, B., Seufert, W., and Varshavsky, A. (1992) EMBO J. 11, 497-505[Medline] [Order article via Infotrieve] |
| 37. |
Johnson, E. S.,
Ma, P. C. M.,
Ota, I. M.,
and Varshavsky, A.
(1995)
J. Biol. Chem.
270,
17442-17456 |
| 38. | Bachmair, A., and Varshavsky, A. (1989) Cell 56, 1019-1032[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Gonda, D. K.,
Bachmair, A.,
Wuenning, I.,
Tobias, J. W.,
Lane, W. S.,
and Varshavsky, A.
(1989)
J. Biol. Chem.
264,
16700-16712 |
| 40. | Seufert, W., Nuber, U., and Huibregste, J. M. (1995) Nature 373, 81-83[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Baker, R. T., Wang, X.-W., Woollatt, E., White, J. A., and Sutherland, G. R. (1999) Genomics, in press |
| 42. |
Huang, Y.,
Baker, R. T.,
and Fischer-Vize, J. A.
(1995)
Science
270,
1828-1831 |
| 43. |
Zhu, Y.,
Carroll, M.,
Papa, F. R.,
Hochstrasser, M.,
and D'Andrea, A. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3275-3279 |
| 44. |
Zhu, Y.,
Lambert, K.,
Corless, C.,
Copeland, N. G.,
Gilbert, D. J.,
Jenkins, N. A.,
and D'Andrea, A. D.
(1997)
J. Biol. Chem.
272,
51-57 |
| 45. |
Ansari-Lari, M. A.,
Muzny, D. M.,
Lu, J.,
Lu, F.,
Lilley, C. E.,
Spanos, S.,
Malley, T.,
and Gibbs, R. A.
(1996)
Genome Res.
6,
314-326 |
| 46. | Timms, K. M., Ansari-Lari, M. A., Morris, W., Brown, S. N., and Gibbs, R. A. (1998) Gene 217, 101-106[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Fischer-Vize, J. A., Rubin, G. A., and Lehmann, R. (1992) Development 116, 985-1000[Abstract] |
| 48. | Frederick, A., Rolfe, M., and Chiu, M. I. (1998) Oncogene 16, 153-165[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Gupta, K., Copeland, N., Gilbert, D., Jenkins, N., and Gray, D. (1993) Oncogene 8, 2307-2310[Medline] [Order article via Infotrieve] |
| 50. | Gupta, K., Chevrette, M., and Gray, D. A. (1994) Oncogene 9, 1729-1731[Medline] [Order article via Infotrieve] |
| 51. | Linnen, J. M., Bailey, C. P., and Weeks, D. L. (1993) Gene 128, 181-188[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Fujiwara, T., Saito, A., Suzuki, M., Shinomiya, H., Suzuki, T., Takahashi, E.-I., Tanigama, A., Ichiyama, A., Chung, C. H., Nakamura, Y., and Tanaka, K. (1998) Genomics 54, 155-158[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. D. Hickman, A. D. Luis, W. Bardet, R. Buchli, C. L. Battson, M. H. Shearer, K. W. Jackson, R. C. Kennedy, and W. H. Hildebrand Cutting Edge: Class I Presentation of Host Peptides Following HIV Infection J. Immunol., July 1, 2003; 171(1): 22 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, X. Na, D. Wang, S. R. Schoen, E. M. Messing, and G. Wu Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein J. Biol. Chem., February 8, 2002; 277(7): 4656 - 4662. [Abstract] [Full Text] [PDF] |
||||
| |||||||||